




RealRate

PHARMACEUTICAL 2022

Aeglea BioTherapeutics Inc.
Rank 342 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2022

Aeglea BioTherapeutics Inc.
Rank 342 of 475



The relative strengths and weaknesses of Aeglea BioTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aeglea BioTherapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Aeglea BioTherapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 145% points.

The company's Economic Capital Ratio, given in the ranking table, is -257%, being 19% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	98,891
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,144
Liabilities, Non-Current	4,624
Other Assets	6,486
Other Compr. Net Income	-31
Other Expenses	141
Other Liabilities	1,217
Other Net Income	-11
Property and Equipment	4,549
Research and Development	57,069
Revenues	18,739
Selling, General and Administrative Expense	27,319

Output Variable	Value in 1000 USD
Assets	109,926
Liabilities	25,985
Expenses	84,529
Stockholders Equity	83,941
Net Income	-65,801
Comprehensive Net Income	-65,816
Economic Capital Ratio	-257%

